XNAS · Healthcare · Drug Manufacturers - General
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Q1 2026 | 2.95 | 3.57 | +21.02% | $2.48B | ✅ Beat | -1.84% | -1.90% | +0.83% |
| 2026-02-06 | Q4 2025 | 1.62 | 1.99 | +22.84% | $2.28B | ✅ Beat | +0.36% | -2.32% | -6.43% |
| 2025-10-30 |
| Q3 2025 |
| 3.89 |
| 4.81 |
| +23.65% |
| $2.53B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-31 | Q2 2025 | 3.91 | 5.47 | +39.90% | $2.65B | ✅ Beat | — | — | — |
| 2025-05-01 | Q1 2025 | 2.52 | 3.02 | +19.84% | $2.43B | ✅ Beat | — | — | — |
| 2025-02-12 | Q4 2024 | 3.35 | 3.44 | +2.69% | $2.46B | ✅ Beat | — | — | — |
| 2024-10-30 | Q3 2024 | 3.79 | 4.08 | +7.65% | $2.47B | ✅ Beat | — | — | — |
| 2024-08-01 | Q2 2024 | 4.02 | 5.28 | +31.34% | $2.46B | ✅ Beat | — | — | — |
Showing last 8 quarters.